硫必利治疗左旋多巴诱发的不自主运动。
Tiapride in levodopa-induced involuntary movements.
作者信息
Lees A J, Lander C M, Stern G M
出版信息
J Neurol Neurosurg Psychiatry. 1979 Apr;42(4):380-3. doi: 10.1136/jnnp.42.4.380.
Abstract
Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease. However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients. Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia. These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.
摘要
硫必利是一种与甲氧氯普胺密切相关的取代苯甲酰胺衍生物，可减少16例特发性帕金森病患者左旋多巴诱导的峰值剂量不自主运动。然而，14例患者因帕金森病导致的残疾不可接受地增加，且剂量末期运动不能加重，导致该药停用。硫必利对左旋多巴诱导的清晨“关期”节段性肌张力障碍无效。这些结果不支持左旋多巴诱导的运动障碍是由另一组多巴胺受体过度刺激引起的这一观点。
相似文献
1
Tiapride in levodopa-induced involuntary movements.硫必利治疗左旋多巴诱发的不自主运动。
J Neurol Neurosurg Psychiatry. 1979 Apr;42(4):380-3. doi: 10.1136/jnnp.42.4.380.
2
[Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
Harefuah. 1985 Mar 1;108(5):227-9.
3
Tiapride in levodopa-induced involuntary movements.
Acta Neurol Scand. 1983 Jun;67(6):372-5. doi: 10.1111/j.1600-0404.1983.tb03155.x.
4
Tiapride in Parkinson's disease.替阿普明在帕金森病中的应用。
Lancet. 1978 Nov 18;2(8099):1106. doi: 10.1016/s0140-6736(78)91850-0.
5
[Therapeutical approach to involuntary movements (author's transl)].
Sem Hop. 1979;55(5-6):262-4.
6
[Value of sulpiride and tiapride in geriatrics. Antagonism between Parkinson disease and chorea].舒必利和硫必利在老年医学中的价值。帕金森病与舞蹈症之间的拮抗作用
Lille Med. 1979 Nov 17;Suppl 1:107-8.
7
[Long-term evaluation of tiapride in patients with various forms of dyskinesia].
No To Shinkei. 1985 Oct;37(10):1013-9.
8
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.DPI-289 是一种新型混合的 delta 阿片受体激动剂/μ 阿片受体拮抗剂（DAMA），在帕金森病中具有节省左旋多巴的潜力。
Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.
9
Morphine in tardive and idiopathic dystonia (short communication).吗啡治疗迟发性和特发性肌张力障碍（简短通讯）
J Neural Transm (Vienna). 2001;108(8-9):1035-41. doi: 10.1007/s007020170022.
10
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.依托必利可对抗帕金森病中左旋多巴诱导的运动障碍：一项剂量探索研究。
Brain. 2015 Apr;138(Pt 4):963-73. doi: 10.1093/brain/awu409. Epub 2015 Feb 10.
引用本文的文献
1
Metoclopramide in tardive dyskinesia.甲氧氯普胺治疗迟发性运动障碍。
Indian J Psychiatry. 1983 Apr;25(2):134-7.
2
Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride.由氟哌啶醇、美齐拉敏以及“抗运动障碍”药物奥昔哌醇和硫必利诱发的猴子急性运动障碍。
Psychopharmacology (Berl). 1981;75(3):254-7. doi: 10.1007/BF00432434.
3
Assessment of extrapyramidal disorders.锥体外系疾病的评估。
Br J Clin Pharmacol. 1981 Feb;11(2):129-51. doi: 10.1111/j.1365-2125.1981.tb01118.x.
4
Effects of tiapride in tardive dyskinesia.舒必利治疗迟发性运动障碍的效果。
Psychopharmacology (Berl). 1985;85(2):236-9. doi: 10.1007/BF00428422.
5
Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease.硫必利在亨廷顿舞蹈症患者中的单次口服剂量药代动力学。
Eur J Clin Pharmacol. 1987;32(6):583-6. doi: 10.1007/BF02455992.
6
Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's disease.
Eur J Clin Pharmacol. 1986;31(2):191-4. doi: 10.1007/BF00606657.
本文引用的文献
1
Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.尝试使用氟哌啶醇治疗左旋多巴诱发的运动障碍。
J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):427-30. doi: 10.1136/jnnp.37.4.427.
2
Metoclopramide--side effects and safety.甲氧氯普胺——副作用与安全性
Postgrad Med J. 1973 Jul;49 Suppl 4:suppl 4:77-80.
3
Heterogeneity of striatal and limbic dopamine innervation: highly fluorescent islands in developing and adult rats.纹状体和边缘系统多巴胺神经支配的异质性：发育中和成年大鼠中的高荧光岛
Brain Res. 1972 Sep 15;44(1):283-8. doi: 10.1016/0006-8993(72)90385-x.
4
The action of dopamine on neurones of the caudate nucleus.多巴胺对尾状核神经元的作用。
J Physiol. 1967 Apr;189(3):393-402. doi: 10.1113/jphysiol.1967.sp008175.
5
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.胃复安和匹莫齐特在帕金森病及左旋多巴诱发的异动症中的应用
J Neurol Neurosurg Psychiatry. 1975 Apr;38(4):331-5. doi: 10.1136/jnnp.38.4.331.
6
Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias.新型多巴胺阻断剂（奥昔哌隆）对帕金森病药物诱发的运动障碍和自发性运动障碍的影响。
Br Med J. 1978 Apr 15;1(6118):954-6. doi: 10.1136/bmj.1.6118.954.
7
Tardive dyskinesia associated with metoclopramide.与甲氧氯普胺相关的迟发性运动障碍。
Br Med J. 1978 Jan 14;1(6105):77-8. doi: 10.1136/bmj.1.6105.77.
8
Baclofen in Parkinson's disease.巴氯芬在帕金森病中的应用。
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):707-8. doi: 10.1136/jnnp.41.8.707.
9
Neuroleptic antagonism of dyskinetic phenomena.抗精神病药物对运动障碍现象的拮抗作用。
Eur J Pharmacol. 1975 Sep-Oct;33(2):301-12. doi: 10.1016/0014-2999(75)90174-0.
10
Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data.兴奋介导和抑制介导的多巴胺受体：一个有助于更好理解电生理、生化、药理、功能及临床数据的新概念。
Psychopharmacologia. 1976 Feb 2;45(3):243-54. doi: 10.1007/BF00421135.
Zotero 插件